{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:59:27Z","timestamp":1783688367946,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.12.002","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:52:33Z","timestamp":1733532753000},"page":"337-348.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-9377","authenticated-orcid":false,"given":"Carrie","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Dhanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol D.","family":"Dhamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-6006","authenticated-orcid":false,"given":"Tao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.12.002_bib0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2024.12.002_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.12.002_bib0003","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2024.12.002_bib0004","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.12.002_bib0005","unstructured":"National Cancer Institute. SEER cancer stat facts: myeloma. Accessed July 25, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"10.1016\/j.clml.2024.12.002_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2024.12.002_bib0007","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2024.12.002_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12703\/r\/11-28","article-title":"Recent advances in the treatment of multiple myeloma: a brief review","volume":"11","author":"Bobin","year":"2022","journal-title":"Fac Rev"},{"key":"10.1016\/j.clml.2024.12.002_bib0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.12.002_bib0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.002_bib0011","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.002_bib0012","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2024.12.002_bib0013","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1186\/s12889-022-14412-1","article-title":"Worldwide cancer statistics of adults over 75 years old in 2019: a systematic analysis of the global burden of disease study 2019","volume":"22","author":"Xiang","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clml.2024.12.002_bib0014","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.12.002_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.12.002_bib0016","unstructured":"Bristol Myers Squibb. REVLIMID (lenalidomide) capsules, for oral use. Prescribing information. Accessed October 10, 2023. https:\/\/packageinserts.bms.com\/pi\/pi_revlimid.pdf."},{"key":"10.1016\/j.clml.2024.12.002_bib0017","unstructured":"Janssen. DARZALEX\u00ae (daratumumab) injection, for intravenous use. Prescribing information. Accessed July 25, 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf."},{"key":"10.1016\/j.clml.2024.12.002_bib0018","unstructured":"Sanofi. SARCLISA (isatuximab-irfc) injection, for intravenous use. Prescribing information. Accessed July 25, 2024. https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf."},{"key":"10.1016\/j.clml.2024.12.002_bib0019","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.18657","article-title":"Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma","volume":"200","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.12.002_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-023-00785-y","article-title":"Defining drug\/drug class refractoriness vs. lines of therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Goel","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.12.002_bib0021","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.12.002_bib0022","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs. carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.12.002_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-024-01039-1","article-title":"Outcomes of patients with multiple myeloma refractory to standard dose vs. low dose lenalidomide","volume":"14","author":"Goel","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.12.002_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.12.002_bib0025","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.12.002_bib0026","unstructured":"European Medicines Agency. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man: methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. Accessed July 25, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/appendix-1-guideline-evaluation-anticancer-medicinal-products-man_en.pdf."},{"key":"10.1016\/j.clml.2024.12.002_bib0027","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.002_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.12.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/832049","article-title":"Deep response in multiple myeloma: a critical review","volume":"2015","author":"Fulciniti","year":"2015","journal-title":"Biomed Res Int."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:34:08Z","timestamp":1751398448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024024418"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}